Literature DB >> 8390660

A brief history of opiates, opioid peptides, and opioid receptors.

M J Brownstein1.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8390660      PMCID： PMC46725          DOI： 10.1073/pnas.90.12.5391

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  24 in total

1.  Cloning of a delta opioid receptor by functional expression.

Authors:  C J Evans; D E Keith; H Morrison; K Magendzo; R H Edwards
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

2.  C fragment of lipotropin has a high affinity for brain opiate receptors.

Authors:  N J Birdsall; E C Hulme
Journal:  Nature       Date:  1976-04-29       Impact factor: 49.962

Review 3.  In vitro models in the study of structure-activity relationships of narcotic analgesics.

Authors:  H W Kosterlitz; A A Waterfield
Journal:  Annu Rev Pharmacol       Date:  1975       Impact factor: 13.820

4.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Regional distribution of opiate receptor binding in monkey and human brain.

Authors:  M J Kuhar; C B Pert; S H Snyder
Journal:  Nature       Date:  1973-10-26       Impact factor: 49.962

6.  Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain.

Authors:  L Terenius
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

7.  Distribution of stereospecific binding of the potent narcotic analgesic etorphine in the human brain: predominance in the limbic system.

Authors:  J M Hiller; J Pearson; E J Simon
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-11

8.  Identification of two related pentapeptides from the brain with potent opiate agonist activity.

Authors:  J Hughes; T W Smith; H W Kosterlitz; L A Fothergill; B A Morgan; H R Morris
Journal:  Nature       Date:  1975-12-18       Impact factor: 49.962

9.  Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.

Authors:  E J Simon; J M Hiller; I Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

10.  Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain.

Authors:  A Goldstein; L I Lowney; B K Pal
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205
View more
  75 in total

1.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 2.  Phytochemicals in the oncology setting.

Authors:  Catherine E Ulbricht; Wendy Chao
Journal:  Curr Treat Options Oncol       Date:  2010-12

3.  Opioid receptor agonists activate pertussis toxin-sensitive G proteins and inhibit adenylyl cyclase in canine cardiac sarcolemma.

Authors:  F Niroomand; R A Mura; L Piacentini; W Kübler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

Review 4.  The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence.

Authors:  Michael J Glass
Journal:  Vitam Horm       Date:  2010       Impact factor: 3.421

Review 5.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 6.  The effects of opiates on the lung.

Authors:  P N Lao
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

7.  Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal.

Authors:  F Simonin; O Valverde; C Smadja; S Slowe; I Kitchen; A Dierich; M Le Meur; B P Roques; R Maldonado; B L Kieffer
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

8.  Opioidergic Agents as Antidepressants: Rationale and Promise.

Authors:  Parnika P Saxena; J Alexander Bodkin
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

9.  Phloem-Specific Expression of Tyrosine/Dopa Decarboxylase Genes and the Biosynthesis of Isoquinoline Alkaloids in Opium Poppy.

Authors:  P. J. Facchini; V. De Luca
Journal:  Plant Cell       Date:  1995-11       Impact factor: 11.277

10.  Enhancement drugs: are there limits to what we should enhance and why?

Authors:  Morten Hesse
Journal:  BMC Med       Date:  2010-08-03       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.